Search

Your search keyword '"Xiao, Lianchun"' showing total 10 results
Start Over Author "Xiao, Lianchun" Journal journal of urology
10 results on '"Xiao, Lianchun"'

1. MP69-11 PREDICTIVE NOMOGRAM FOR POST-NEPHROURETERECTOMY GFR ESTIMATION

Author

Hensley, Patrick, primary, Labbate, Craig, additional, Xiao, Lianchun, additional, Zganjar, Andrew, additional, Durdin, Trey, additional, Huelster, Heather, additional, Pham, Jonathan, additional, Howard, Jeffrey, additional, Pallauf, Maximilian, additional, Lombardo, Kara, additional, Potretzke, Aaron, additional, Spiess, Philippe, additional, Raman, Jay, additional, Margulis, Vitaly, additional, Singla, Nirmish, additional, Coleman, Jonathan, additional, and Matin, Surena, additional

Published
2023
Full Text
View/download PDF

2. LBA01-10 INTERIM RESULTS FROM A PHASE 1B CLINICAL TRIAL EVALUATING TOLERABILITY AND ACTIVITY OF FGFR INHIBITION IN LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA (UTUC)

Author

Matin, Surena, primary, Adibi, Mehrad, additional, Shah, Amishi, additional, Alhalabi, Omar, additional, Corn, Paul, additional, Guo, Charles, additional, Amirtharaj, Rhenita, additional, Lozano, Marisa, additional, Xiao, Lianchun, additional, Pal, Sumanta, additional, and Campbell, Matthew, additional

Published
2022
Full Text
View/download PDF

5. PD48-08 CLINICAL AND PATHOLOGICAL OUTCOMES FOR PATIENTS WITH HIGH RISK T1HG BLADDER CANCER MANAGED WITH EITHER UPFRONT CYSTECTOMY OR PRIMARY BCG AND DELAYED CYSTECTOMY

Author

Roger Li, James E. Ferguson, Michael J. Metcalfe, Xiao Lianchun, Colin P.N. Dinney, Neema Navai, Ashish M. Kamat, and Jay B. Shah

Subjects
Oncology, Cystectomy, medicine.medical_specialty, Bladder cancer, business.industry, Urology, Internal medicine, medicine.medical_treatment, medicine, business, medicine.disease, Pathological
Published
2017

8. MP78-02 RESULTS OF SECOND LINE TOPICAL THERAPY FOR UPPER TRACT UROTHELIAL CARCINOMA (UTUC)

Author

Balasubramanian, Adithya, primary, Metcalfe, Michael J, additional, Wagenheim, Gavin, additional, Xiao, Lianchun, additional, Petros, Firas G, additional, Papadopoulos, John, additional, Navai, Neema, additional, Davis, John W, additional, Karam, Jose A, additional, Kamat, Ashish M, additional, Wood, Christopher G, additional, Dinney, Colin P, additional, and Matin, Surena F, additional

Published
2017
Full Text
View/download PDF

10. Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.

Author

Matin SF, Adibi M, Shah AY, Alhalabi O, Corn P, Guo C, Amirtharaj R, Xiao L, Lange S, Duose DY, Wang S, Pal S, and Campbell MT

Subjects
Humans, Male, Female, Aged, Middle Aged, Receptor, Fibroblast Growth Factor, Type 3 antagonists & inhibitors, Receptor, Fibroblast Growth Factor, Type 3 genetics, Kidney Neoplasms drug therapy, Kidney Neoplasms surgery, Kidney Neoplasms pathology, Ureteroscopy adverse effects, Nephroureterectomy, Aged, 80 and over, Treatment Outcome, Phenylurea Compounds, Pyrimidines, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell surgery, Carcinoma, Transitional Cell pathology, Carcinoma, Transitional Cell genetics, Ureteral Neoplasms drug therapy, Ureteral Neoplasms surgery, Ureteral Neoplasms pathology
Abstract

Purpose: We initiated a biomarker-informed preoperative study of infigratinib, a fibroblast growth factor receptor (FGFR) inhibitor, in patients with localized upper tract urothelial carcinoma (UTUC), a population with high unmet needs and tumor with a high frequency of FGFR3 alterations., Materials and Methods: Patients with localized UTUC undergoing ureteroscopy or nephroureterectomy/ureterectomy were enrolled on a phase 1b trial (NCT04228042). Once-daily infigratinib 125 mg by mouth × 21 days (28-day cycle) was given for 2 cycles. Tolerability was monitored by Bayesian design and predefined stopping boundaries. The primary endpoint was tolerability, and the secondary endpoint was objective response based on tumor mapping, done after endoscopic biopsy and post-trial surgery. Total planned enrollment: 20 patients. Targeted sequencing performed using a NovaSeq 6000 solid tumor panel., Results: From May 2021 to November 2022, 14 patients were enrolled, at which point the trial was closed due to termination of all infigratinib oncology trials. Two patients (14.3%) had treatment-terminating toxicities, well below the stopping threshold. Responses occurred in 6 (66.7%) of 9 patients with FGFR3 alterations. Responders had median tumor size reduction of 67%, with 3 of 5 patients initially planned for nephroureterectomy/ureterectomy converted to ureteroscopy. Median follow-up in responders was 24.7 months (14.9-28.9)., Conclusions: In this first trial of targeted therapy for localized UTUC, FGFR inhibition was well tolerated and had significant activity in FGFR3 altered tumors. Renal preservation was enabled in a substantial proportion of participants. These data support the design of a biomarker-driven phase 2 trial of FGFR3 inhibition in this population with significant unmet clinical needs.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results